Q32 Bio Secures $55 Million FinancingQ32 Bio disclosed Wednesday that it entered into a securities purchase agreement to raise approximately $55 million through a private placement.The company will issue 6.725 million shares of common stock at $8 per share, along with pre-funded warrants to purchase an additional 150,000 shares.The financing is expected to close on May 28, subject to customary closing conditions. Proceeds are expected to support the continued development of the company’s therapies targeting alopecia areata and other immune-mediated diseases.QTTB Technical OutlookQTTB is in a strong longer-term uptrend, with the stock up 540.21% over the past 12 months and trading well above its major moving averages. It’s currently trading 92.6% above the 20-day SMA ($6.28) and 211.1% above the 200-day SMA ($3.89), which underscores how stretched the trend has become.Trend structure remains bullish. The 20-day SMA is above the 50-day SMA, and the 50-day SMA is above the 200-day SMA (a golden cross that occurred in October 2025). From a “where are we in the swing?” perspective, the recent swing low was in April and the recent swing high was in May, aligning with the stock’s push toward its upper range.For momentum, MACD is the cleaner read right now. It’s above its signal line and the histogram is positive, which points to improving upside momentum versus the prior downswing. In plain terms, when MACD is above the signal line, it suggests buyers are regaining control and downside pressure is easing.